抑制microRNA-138可促进多发性骨髓瘤骨髓生态位的骨形成
本研究探讨microRNA-138(miR-138)在多发性骨髓瘤(MM)骨病中的作用,并评估全身递送锁核酸(LNA)修饰的抗miR-138寡核苷酸抑制骨髓瘤骨病的潜力。结果显示,MM患者间充质基质细胞(MM-MSC)和骨髓瘤细胞中miR-138表达较健康受试者显著升高;抑制miR-138可增强MM-MSC体外成骨分化,并增加骨髓瘤骨病小鼠模型中骨内膜成骨谱系细胞(OBC)数量和骨形成率。OBC的RNA测序鉴定出TRPS1和SULF2为抗miR-138处理小鼠中去抑制的潜在miR-138靶点。
要点
- MM患者MSC和骨髓瘤细胞中miR-138表达较健康受试者显著升高。
- 抑制miR-138可增强MM-MSC体外成骨分化。
- 抗miR-138处理增加骨髓瘤骨病小鼠骨内膜OBC数量和骨形成率。
核心结论
- 抑制miR-138可促进MM中的骨形成。
- 药理学抑制miR-138可能成为治疗骨髓瘤骨病的新治疗策略。
研究设计与样本
- 研究比较MM患者与健康受试者MSC及骨髓瘤细胞中miR-138表达。
- 体外评估抑制miR-138对MM-MSC成骨分化的影响。
- 在骨髓瘤骨病小鼠模型中评估全身递送LNA修饰抗miR-138寡核苷酸的效果,并对OBC进行RNA测序。
主要发现
- MM-MSC和骨髓瘤细胞中miR-138表达较健康受试者显著升高。
- 抑制miR-138导致MM-MSC体外成骨分化增强。
- 抗miR-138处理增加骨髓瘤骨病小鼠模型中骨内膜OBC数量和骨形成率。
- RNA测序鉴定出TRPS1和SULF2为抗miR-138处理小鼠OBC中去抑制的潜在miR-138靶点。
临床怎么用
- 原文结论指出药理学抑制miR-138可能成为治疗骨髓瘤骨病的新治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloma bone disease is a devastating complication of multiple myeloma (MM) and is caused by dysregulation of bone remodeling processes in the bone marrow microenvironment. Previous studies showed that microRNA-138 (miR-138) is a negative regulator of osteogenic differentiation of mesenchymal stromal cells (MSCs) and that inhibiting its function enhances bone formation in vitro. In this study, we explored the role of miR-138 in myeloma bone disease and evaluated the potential of systemically delivered locked nucleic acid (LNA)-modified anti-miR-138 oligonucleotides in suppressing myeloma bone disease. We showed that expression of miR-138 was significantly increased in MSCs from MM patients (MM-MSCs) and myeloma cells compared to those from healthy subjects. Furthermore, inhibition of miR-138 resulted in enhanced osteogenic differentiation of MM-MSCs in vitro and increased the number of endosteal osteoblastic lineage cells (OBCs) and bone formation rate in mouse models of myeloma bone disease. RNA sequencing of the OBCs identified TRPS1 and SULF2 as potential miR-138 targets that were de-repressed in anti-miR-138-treated mice. In summary, these data indicate that inhibition of miR-138 enhances bone formation in MM and that pharmacological inhibition of miR-138 could represent a new therapeutic strategy for treatment of myeloma bone disease.
引用
- Tsukamoto S, Løvendorf MB, Park J, et al. Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. Leukemia. 2018. PMID: 29925904. doi:10.1038/s41375-018-0161-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。